MX2023003825A - Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. - Google Patents

Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados.

Info

Publication number
MX2023003825A
MX2023003825A MX2023003825A MX2023003825A MX2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A
Authority
MX
Mexico
Prior art keywords
treatment
thiadiazolone
diabetes
derivatives
related disorders
Prior art date
Application number
MX2023003825A
Other languages
English (en)
Spanish (es)
Inventor
Jacob Westman
Thomas Edlund
Original Assignee
Betagenon Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Bio Ab filed Critical Betagenon Bio Ab
Publication of MX2023003825A publication Critical patent/MX2023003825A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023003825A 2020-10-01 2021-09-30 Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. MX2023003825A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2015585.9A GB202015585D0 (en) 2020-10-01 2020-10-01 New compounds
PCT/GB2021/052535 WO2022069894A1 (en) 2020-10-01 2021-09-30 Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders

Publications (1)

Publication Number Publication Date
MX2023003825A true MX2023003825A (es) 2023-06-06

Family

ID=73223766

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003825A MX2023003825A (es) 2020-10-01 2021-09-30 Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados.

Country Status (13)

Country Link
US (1) US12643918B2 (cg-RX-API-DMAC7.html)
EP (1) EP4222147B1 (cg-RX-API-DMAC7.html)
JP (1) JP7793614B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079163A (cg-RX-API-DMAC7.html)
CN (1) CN116368141B (cg-RX-API-DMAC7.html)
AU (1) AU2021352146A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193947A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018732T3 (cg-RX-API-DMAC7.html)
GB (1) GB202015585D0 (cg-RX-API-DMAC7.html)
HU (1) HUE071685T2 (cg-RX-API-DMAC7.html)
MX (1) MX2023003825A (cg-RX-API-DMAC7.html)
PL (1) PL4222147T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022069894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202112529D0 (en) * 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
JPWO2024075784A1 (cg-RX-API-DMAC7.html) * 2022-10-05 2024-04-11

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010270030B2 (en) 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
GB201915094D0 (en) 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
CN122421964A (zh) 2023-07-20 2026-07-17 塔吉农有限责任公司 使用双重ampk激活剂和线粒体解偶联剂调节血糖水平的方法
JP2026526085A (ja) 2023-07-20 2026-08-05 ベタゲノン アーベー 代謝非柔軟性により誘発される心筋症の治療方法
CN121925257A (zh) 2023-08-03 2026-04-24 塔吉农有限责任公司 用pdk抑制剂4-氯-n-(2-(4-氯苄基)-3-氧代-2,3-二氢-1,2,4-噻二唑-5-基)苯甲酰胺治疗癌症
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Also Published As

Publication number Publication date
ES3018732T3 (en) 2025-05-19
GB202015585D0 (en) 2020-11-18
PL4222147T3 (pl) 2025-06-09
EP4222147B1 (en) 2025-03-19
CN116368141A (zh) 2023-06-30
HUE071685T2 (hu) 2025-09-28
JP2023543924A (ja) 2023-10-18
CA3193947A1 (en) 2022-04-07
KR20230079163A (ko) 2023-06-05
AU2021352146A1 (en) 2023-06-01
US12643918B2 (en) 2026-06-02
WO2022069894A1 (en) 2022-04-07
JP7793614B2 (ja) 2026-01-05
EP4222147A1 (en) 2023-08-09
EP4222147C0 (en) 2025-03-19
US20230382930A1 (en) 2023-11-30
CN116368141B (zh) 2025-09-23

Similar Documents

Publication Publication Date Title
MX2023013339A (es) Inhibidor del factor b del complemento, y composicion farmaceutica del mismo, metodo de preparacion del mismo y uso del mismo.
CO6382083A2 (es) Compuestos triciclicos novedosos
DOP2012000151A (es) Nuevos compuestos triciclicos
MX2020000261A (es) Nuevos compuestos.
MX2023001876A (es) Derivados de rapamicina.
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
CU20120015A7 (es) Piridina y pirazina como derivados de moduladores de la proteína kinasa
CU20210035A7 (es) Compuestos de azalactam como inhibidores de hpk 1
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
UY35630A (es) Carboxamidas primarias como inhibidores de btk
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
DOP2012000058A (es) Agente terapeutico para trastornos del estado de animo
CR20130530A (es) Derivados glucósidos y sus usos para el tratamiento de la diabetes
CR20170496A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
DOP2025000212A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
BR112023012947A2 (pt) Inibidores de lrrk2
ECSP13013026A (es) Isoxazolinas como agentes terapéuticos
PY1886949A (es) Inhibidor del receptor del factor de crecimiento epidérmico
MX2024001270A (es) Compuestos heterociclicos para el tratamiento de la epilepsia.
MX2024002674A (es) Derivados de tiadiazolona utiles como activadores de ampk.
UY31824A (es) Nuevos compuestos
UY35223A (es) Moduladores heterocíclicos de receptores de hormonas nucleares
DOP2012000056A (es) Agente terapeutico para trastornos de ansiedad